Rockwell Medical Names Heather Hunter SVP, Chief Corporate Affairs Officer
September 07 2022 - 8:00AM
Business Wire
Rockwell Medical, Inc. (Nasdaq: RMTI), a commercial healthcare
company focused on providing life-sustaining products for patients
suffering from blood disorders and diseases associated with the
kidney, today announced that Heather Hunter has joined the Company
as SVP, Chief Corporate Affairs Officer. In this role, Heather will
be responsible for the Company’s investor relations, media
relations, government affairs, patient advocacy, communications,
and branding.
“Heather brings more than two decades of executive leadership,
investor relations and communications expertise to Rockwell, with a
wealth of experience in the capital markets and a strong network
across the financial community,” said Mark Strobeck, Ph.D.,
President and CEO at Rockwell. “Heather has a demonstrated track
record of success elevating corporate brands, developing and
implementing corporate strategy, and driving shareholder value. I
look forward to working with Heather as we unlock the value of our
product portfolio and development expertise and transition our
business towards profitability.”
“I am excited for the path that lies ahead at Rockwell and
impressed by all that the Company has achieved in its 25+ year
history,” said Heather. “Rockwell is at a critical inflection point
as the Company works towards profitability and expands its
portfolio of offerings for patients suffering from blood disorders
and diseases associated with the kidney. I look forward to working
with Mark and the rest of the Rockwell team to catalyze and support
the Company’s success now and into the future.”
Prior to joining Rockwell, Heather led communications at
Venatorx Pharmaceuticals, a private, pre-commercial anti-infectives
pharmaceutical company; Safeguard Scientifics (NYSE:SFE), a growth
equity investor focused on early- and growth-stage healthcare and
technology companies; and W.P. Carey (NYSE:WPC), one of the largest
net lease real estate investment trusts. Heather is currently an
Advisory Board Member at Journal My Health, a digital health
platform designed to empower patients with chronic health
conditions to use their data to achieve better health outcomes, and
a Managing Director at Golden Seeds, an angel investment firm that
funds revenue-stage, women-led and women-founded companies. Heather
was named to the Philadelphia Business Journal ‘40 Under 40’ list
in 2017 and received a B.A. in History from Yale University.
About Rockwell Medical
Rockwell Medical is a commercial healthcare company focused on
providing life-sustaining products for patients suffering from
blood disorders and diseases associated with the kidney. Rockwell
is the second largest supplier of acid and bicarbonate concentrates
for dialysis patients in the United States. The Company is
developing and commercializing a next-generation, proprietary
parenteral iron technology platform, Ferric Pyrophosphate Citrate
(“FPC”), which has the potential to transform treatment options for
iron deficiency in multiple disease states, reduce healthcare costs
and improve patients' lives. Rockwell has two FDA-approved
therapies indicated for patients undergoing hemodialysis, which are
the first two products developed from the FPC platform. Rockwell is
also advancing its FPC platform by developing FPC for the treatment
of iron deficiency anemia in patients outside of dialysis, who are
receiving medications in the home infusion setting. For more
information, visit www.RockwellMed.com.
Forward-Looking Statements
Certain statements in this press release may constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as, "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue," "could,"
"can," "would," "develop," "plan," "potential," "predict,"
"forecast," "project," "intend," "look forward to," "remain
confident" or the negative of these terms, and similar expressions,
or statements regarding intent, belief, or current expectations,
are forward looking statements. There can be no assurance that
Rockwell Medical will be able to maintain timing for planned
clinical trials and regulatory filings, achieve planned cost
savings to operate its concentrates business profitability, or
achieve the other components of its strategy. While Rockwell
Medical believes these forward-looking statements are reasonable,
undue reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward-looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties (including, without limitation, those set
forth in Rockwell Medical's SEC filings), many of which are beyond
our control and subject to change. Actual results could be
materially different. Risks and uncertainties include, but are not
limited to those risks more fully discussed in the "Risk Factors"
section of our Annual Report on Form 10-K for the year ended
December 31, 2021, as such description may be amended or updated in
any future reports we file with the SEC. Rockwell Medical expressly
disclaims any obligation to update our forward-looking statements,
except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220907005417/en/
Heather R. Hunter (248) 432-1362 IR@RockwellMed.com
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Sep 2023 to Sep 2024